Laseena Vaisyambath

Dr. Laseena Vaisyambath


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Cureus
Verified
Journal Article
Open access
RJRicha Jaiswal
Richa Jaiswal
LVLaseena Vaisyambath
Laseena Vaisyambath
AKAzadeh Khayyat
Azadeh Khayyat
NUNkechinyere Unachukwu
Nkechinyere Unachukwu
BNBibimariyam Nasyrlaeva
Bibimariyam Nasyrlaeva
RRRizwan Rabbani
Rizwan Rabbani
Sarcoidosis can be presented as cardiac sarcoidosis (CS), which is challenging to diagnose due to its clinical silence. Ventricular arrhythmias and atrioventricular blocks can be fatal and cause sudden death in patients with cardiac sarcoidosis. Five percent of sarcoidosis patients have clinically evident cardiac sarcoidosis. However, autopsy reports and imaging studies have shown a higher prevalence of cardiac involvement. Early recognition is important to prevent such detrimental consequences. Cardiac sarcoidosis is increasingly being diagnosed owing to increased awareness among physicians and new diagnostic tools like MRI and positron emission tomography (PET) scan replacing traditional endomyocardial biopsy. A definitive diagnosis of CS remains challenging due to the non-specific clinical findings that can present similar symptoms of common cardiac disease; therefore, the imaging and biopsies are substantial for diagnosis confirmation. Pharmacological and Implantable devices are two main therapeutic approaches in cardiac sarcoidosis, in which steroids and pacemaker therapy have shown better outcomes. This review summarizes the available data related to the prevalence, prognosis, diagnosis, and management of cardiac sarcoidosis.

9 March 2022 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
APArpankumar Patel
Arpankumar Patel
Rutikbhai DesaiRutikbhai Desai
Rutikbhai Desai
HSHilloni Shah
Hilloni Shah
LVLaseena Vaisyambath
Laseena Vaisyambath
MKManozna Karri
Manozna Karri
TKThoyaja koritala
Thoyaja koritala

18 September 2023 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
PMPreeti Malik
Preeti Malik
NPNeel Patel
Neel Patel
AKazadeh khayyat
azadeh khayyat
MAMuhammad Asad
Muhammad Asad
SDSameer Dawoodi
Sameer Dawoodi
Urvish PatelUrvish Patel
Urvish Patel
Background: Neuroendocrine tumors (NET) are a rare group of epithelial neoplasms present in the gastrointestinal tract (GI) (67.5%) and bronchopulmonary tree (25.3–30%), and in 15% of cases, their primary sites cannot be identified. Although endoscopic screening, improvements in pathological techniques, and early detection have shown improvements in NET survival rates, the prognosis of advanced, metastatic, and poorly differentiated NET is very poor. In this study, we aimed to evaluate the effect of gastrointestinal and pancreatic (GEPs) NETs’ grade on overall survival. Method: We searched observational studies describing the overall survival or prognostic factors of primary GEP NETs from May 2011–May 2021 following the PRISMA guidelines. Studies describing the effect of primary grade 3 GEP NETs on overall survival were included. A meta-analysis was performed, and a pooled hazard ratio and their 95% confidence interval (95% CI) were obtained. Forest plots were created using random effects models and a sensitivity analysis was performed to account for the heterogeneity. Results: Seven studies with 7692 confirmed patients were included. In our meta-analysis, grade 3 GEP NETs were associated with higher odds of poor survival (pooled HR: 2.73; 95% CI: 1.36–5.47; p = 0.005), with a 92% heterogeneity between studies (p < 0.0001). To account for this heterogeneity, a sensitivity analysis was performed by removing two outlying studies (Fathi et al. and Foubert et al.) on funnel plots. The results after the sensitivity analysis did not change and still showed a significant association of grade 3 with a poor survival (pooled HR: 4.53; 95% CI: 3.54–5.78; p < 0.00001), with no heterogeneity between studies (p = 0.72; I2 = 0%). Conclusions: Our meta-analysis found that grade 3 GEP NETs are associated with poor survival and additional future studies are needed to identify other risk factors associated with poor survival in GEP NETs to improve their mortality.